BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $MRNA readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07496450-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:mRNA-1018-H5 readout (P3) · ModernaTX\, Inc. $MRNA
DESCRIPTION:A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy A
 dults\n\nPrimary completion date: 2027-01-28 (estimated)\nPhase 3 · Infec
 tious · Influenza\nEnrollment: 4050 · Sites: 35\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07
 496450\nhttps://clinicaltrials.gov/study/NCT07496450
URL:https://datacutoff.com/radar.html?nct=NCT07496450
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592794-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Nova 301 readout (P3) · ModernaTX\, Inc. $MRNA
DESCRIPTION:A Study to Investigate the Safety and Efficacy of mRNA-1403 in 
 Participants ≥18 Years of Age for the Prevention of Acute Gastroenteriti
 s\n\nPrimary completion date: 2027-02-15 (estimated)\nOriginally planned: 
 2027-05-31 (-3.4 months)\nPhase 3 · GI·Renal·Heme · Acute Gastroenteri
 tis\, Norovirus Acute Gastroenteritis\nEnrollment: 37864 · Sites: 283\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT06592794\nhttps://clinicaltrials.gov/study/NCT06592794
URL:https://datacutoff.com/radar.html?nct=NCT06592794
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683457-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270306
DTEND;VALUE=DATE:20270307
SUMMARY:mRNA-1647 readout (P2) · ModernaTX\, Inc. $MRNA
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, and Immunogenicity 
 of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell
  Transplantation (HCT) Participants.\n\nPrimary completion date: 2027-03-0
 6 (estimated)\nOriginally planned: 2025-02-01 (+25.1 months)\nPhase 2 · I
 nfectious · Cytomegalovirus Infection\nEnrollment: 84 · Sites: 3\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT05683457\nhttps://clinicaltrials.gov/study/NCT05683457
URL:https://datacutoff.com/radar.html?nct=NCT05683457
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
